Janssens, Ann
Berneman, Zwi N.
Offner, Fritz
Snauwaert, Sylvia
Mineur, Philippe
Vanstraelen, Gaetan
Meers, Stef
Spoormans, Isabelle
Bron, Dominique
Vande Broek, Isabelle
Van Bogaert, Charlotte
De Beleyr, Birgit
Smet, Ann
Nielsen, Lasse
Wapenaar, Robert
André, Marc
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 11 August 2022
Accepted: 16 September 2022
First Online: 13 October 2022
Declarations
:
: AJ reports consultancy for Janssen, Roche, Gilead, AbbVie, Novartis, Amgen, Sanofi-Genzyme and Celgene; research grant from Janssen; travel grant from Janssen, Celgene, AbbVie and Roche. ZNB reports research grants from Janssen, Roche, Takeda, CAF-DCF. SM reports consultancy for Janssen. DB reports consultancy and research grant from Janssen. FO reports research grants from Janssen. MA reports consultancy for Takeda, Bristol Myers Squibb, Karyopharm, Gilead and Incyte; research grants from Roche, Johnson & Johnson and Takeda; travel grants from Roche, Bristol Myers Squib, Celgene, Gilead and AbbVie. CVB, BDB, AS, LN and RW are employees of Janssen-Cilag. BDB reports stock ownership from Johnson & Johnson and Pfizer. RW reports stock ownership from Johnson & Johnson. IS, GV, PM, SS and IVB ZB have no conflicts to report.
: The study protocol was approved by the institutional review boards or independent ethics committees of participating centers. All patients received oral and written information on the study and provided informed consent to data collection and source data verification.